The First-Ever FDA-Approved Alternative to Warfarin Carries a Serious Risk of Bleeding

It was the first-ever FDA-approved blood thinner alternative to warfarin — and it still may carry a serious risk of bleeding.

Unfortunately, it’s not always a good thing to be the first to the table. Pradaxa’s risk for serious bleeding is so serious that patients who take the blood thinner are at risk of internal bleeding that could require hospitalization.

Pradaxa is commonly prescribed to help reduce the risk of blood clots and strokes in patients with atrial fibration (— or, “AFib”). It’s also often prescribed to patients with pulmonary embolism (PE) or deep vein thrombosis (DVT).

When Pradaxa was approved as the first-ever alternative to Warfarin by the FDA in 2010, patients around the country were happy to hear that there was a new blood thinner on the market that required less doctor visits, labs and changes to their diet and lifestyle. In the last five years, almost 10 million Pradaxa prescriptions have been filled in the U.S. alone, showing just how popular all of these benefits were to patients.

People were excited, alright. But could that excitement have been encouraged by the fact that necessary information was left out of the picture? Necessary information like: The risk for bleeding?

We think we’re onto something. And we think people who take blood thinners and rely on them for their various health concerns deserve so, so much more.

If you or someone you know suffered from serious bleeding after taking Pradaxa — or even have a loved one who passed away after taking Pradaxa — contact a lawyer from Baron & Budd at 866-795-8339 or complete our contact form. You may be able to file a blood thinner lawsuit to get the answers we all so desperately need.

News Articles

View All
  • Get Answers Now

    Get a free case evaluation to help determine your legal rights.

  • Receive emails from Baron & Budd?
  • Receive text messages from Baron & Budd?
  • This field is for validation purposes and should be left unchanged.